Local immunomodulation for cancer therapy: Providing treatment where needed

Abstract

In murine models of cancer, we have achieved efficient systemic activation of tumor-specific T cells by the local administration of a CTLA4-blocking antibody at low doses. Using a slow-release formulation, we could drastically lower the serum levels of the antibody, hence decreasing adverse effects and the risk of autoimmune reactions, without losing systemic efficacy.

Keywords::

• CTLA-4
• abscopal effect
• side-effects
• immunomodulating
• local treatment